Investors Sell Becton Dickinson and (BDX) on Strength on Insider Selling

Investors sold shares of Becton Dickinson and Co (NYSE:BDX) on strength during trading on Monday following insider selling activity. $105.46 million flowed into the stock on the tick-up and $190.09 million flowed out of the stock on the tick-down, for a money net flow of $84.63 million out of the stock. Of all stocks tracked, Becton Dickinson and had the 0th highest net out-flow for the day. Becton Dickinson and traded up $1.75 for the day and closed at $218.89Specifically, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is owned by company insiders.

A number of analysts have recently weighed in on BDX shares. Wells Fargo & Co reissued a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Argus raised their price target on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp started coverage on shares of Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 price target for the company. Bank of America reissued a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Finally, Morgan Stanley raised their price target on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $237.27.

The firm has a market capitalization of $49,410.00, a price-to-earnings ratio of 164.43, a P/E/G ratio of 1.49 and a beta of 1.12. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.33 earnings per share. analysts anticipate that Becton Dickinson and Co will post 10.95 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.

Institutional investors have recently added to or reduced their stakes in the business. Legacy Advisors LLC lifted its stake in Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 490 shares during the last quarter. Amica Retiree Medical Trust lifted its stake in Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 390 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Becton Dickinson and in the fourth quarter valued at $109,000. FTB Advisors Inc. lifted its stake in Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 290 shares during the last quarter. Finally, Advisors Preferred LLC bought a new stake in Becton Dickinson and in the fourth quarter valued at $126,000. 75.56% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Investors Sell Becton Dickinson and (BDX) on Strength on Insider Selling” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/investors-sell-becton-dickinson-and-bdx-on-strength-on-insider-selling.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply